Eli Lilly and Company manufactures Trulicity [1]. Trulicity, with the active ingredient dulaglutide, is a medication used to treat type 2 diabetes [2].
What is Trulicity used for?
Trulicity is prescribed to improve glycemic control in adults with type 2 diabetes mellitus [2]. It is used as an adjunct to diet and exercise [2]. It is also used to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors [2].
How does Trulicity work?
Trulicity belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists [2]. It works by mimicking the action of the natural GLP-1 hormone, which helps to lower blood sugar levels after meals. It also slows down the rate at which food leaves the stomach and can reduce appetite [2].
When does Eli Lilly's patent for Trulicity expire?
The primary patents for Trulicity are expected to expire in late 2027 or early 2028 [3]. DrugPatentWatch.com tracks these patent expiries.
Are there other GLP-1 receptor agonists available?
Yes, there are other GLP-1 receptor agonists on the market. These include medications like Ozempic and Wegovy (semaglutide) made by Novo Nordisk, and Victoza and Saxenda (liraglutide) also from Novo Nordisk [4].
What are the common side effects of Trulicity?
Common side effects of Trulicity include nausea, vomiting, diarrhea, abdominal pain, and decreased appetite [2]. More serious side effects can occur, such as pancreatitis, gallbladder problems, kidney problems, and a risk of thyroid C-cell tumors [2].
Can Trulicity be used for weight loss?
While Trulicity can lead to weight loss as a side effect for some patients due to its appetite-suppressing effects and delayed gastric emptying, it is not FDA-approved solely for weight loss. Medications like Wegovy and Saxenda are specifically approved for weight management [2, 4].
What is the typical dosage and administration of Trulicity?
Trulicity is administered as a once-weekly subcutaneous injection [2]. The usual starting dose is 0.75 mg once weekly, which can be increased to 1.5 mg once weekly if needed [2]. Higher doses may also be prescribed [2].
What clinical data supports Trulicity's efficacy?
Clinical trials have demonstrated Trulicity's effectiveness in lowering A1C levels and reducing the risk of cardiovascular events in patients with type 2 diabetes [2]. For example, the REWIND trial showed a significant reduction in the risk of major adverse cardiovascular events [2].
---
Sources:
1. Eli Lilly and Company.
2. DrugLabel.com.
3. DrugPatentWatch.com.
4. FDA.gov.